PubRank

B Bottasso

Author PubWeight™ 20.44‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol 2004 1.59
2 Poor comparability of prothrombin fragment 1 + 2 values measured by two commercial ELISA methods: influence of different anticoagulants and standards. Thromb Haemost 1994 1.38
3 Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 1997 1.15
4 Hypercoagulability in centenarians: the paradox of successful aging. Blood 1995 1.08
5 Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol 1984 0.99
6 Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner. Clin Exp Immunol 1999 0.91
7 High-D-dimer plasma levels predict poor outcome in esophageal variceal bleeding. Dig Liver Dis 2008 0.86
8 Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost 1992 0.84
9 Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. J Endocrinol Invest 2000 0.83
10 Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon. Scand J Rheumatol 2004 0.83
11 Composition of platelet phospholipids after moderate consumption of red wine in healthy volunteers. Eur J Clin Nutr 1996 0.81
12 Hemostasis abnormalities in patients with vascular dementia and Alzheimer's disease. Thromb Haemost 1996 0.80
13 Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. Int J Microcirc Clin Exp 1992 0.79
14 Protein C antigen during pregnancy, delivery and puerperium. Thromb Haemost 1984 0.79
15 Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol 1997 0.79
16 Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma. Exp Clin Endocrinol Diabetes 2000 0.78
17 Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemost 1996 0.77
18 In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris. Arterioscler Thromb Vasc Biol 2000 0.77
19 Bradykinin in the ascitic fluid of patients with liver cirrhosis. Clin Sci (Lond) 2001 0.76
20 High plasma levels of protein C activity and antigen in the nephrotic syndrome. Thromb Haemost 1986 0.76
21 Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Exp Clin Endocrinol Diabetes 2000 0.76
22 Prothrombin fragment 1 + 2 and intensity of treatment with oral anticoagulants. Thromb Haemost 1991 0.75
23 Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 1990 0.75
24 Changes in fibrinolysis in patients with localized tumors. Eur J Cancer 1990 0.75
25 Treatment with stanozolol of type I protein C deficiency in an Italian family. Ric Clin Lab 1985 0.75
26 Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia. Thromb Res 1993 0.75
27 Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers. Thromb Res 1991 0.75
28 Comparison of a functional assay for protein C with two immunoassays. Thromb Res 1985 0.75
29 Markers of procoagulant imbalance in patients with localized melanomas and autoimmune disorders. Br J Haematol 1993 0.75
30 Fibrinolytic response in normal subjects to venous occlusion and DDAVP infusion. Thromb Res 1989 0.75
31 Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis. J Rheumatol 2001 0.75
32 L-arginine therapy in Raynaud's phenomenon? Int J Clin Lab Res 1991 0.75
33 [Additional contribution of high amplification electrocardiography in the follow-up of children with muscular dystrophy]. Arch Mal Coeur Vaiss 1991 0.75
34 t-PA activity elicited by venous occlusion or DDAVP infusion does not produce plasmin activity in normal subjects. Thromb Res 1990 0.75
35 Elevation of thrombin-antithrombin complexes during thrombolytic therapy in patients with myocardial infarction. Ric Clin Lab 1990 0.75
36 DDAVP infusion does not affect plasma levels of endothelin-1 in four normal subjects. Thromb Haemost 1992 0.75